FDA approves Exelon®Patch
Today, the Food and Drug Administration approved the Exelon Patch (rivastigmine transdermal system), the first and only skin patch for the treatment of mild to moderate Parkinson’s disease dementia and mild to moderate Alzheimer’s disease in the U.S. As you know, Parkinson's disease dementia is a distinct and common disorder, characterized by impairments in executive function, memory retrieval, and attention, in patients with an established diagnosis of Parkinson’s disease for at least two years. Two out of five people with Parkinson’s disease are estimated to have Parkinson’s disease dementia.
Exelon Patch Benefits:
Once-daily skin patch offers novel approach to treating mild to moderate Parkinson’s disease dementia and Alzheimer’s disease, providing smooth and continuous delivery of drug over 24 hours
The Exelon Patch greatly reduces the gastrointestinal side effects commonly seen with this class of drugs, called cholinesterase inhibitors, with three times fewer reports of nausea and vomiting than with the capsule form of the drug.
In a study of Alzheimer’s disease caregivers, the patch was preferred to capsules by 70% of caregivers as a method of drug delivery, because it helped them follow the treatment schedule, interfered less with their daily life, and was easier to use overall than an oral medication